Urinary tract infections (UTIs) caused by uropathogenic Escherichia coli (UPEC) are a significant health concern, exacerbated by the rapid emergence of multidrug resistant strains refractory to antibiotic treatment. P fimbriae are strongly associated with upper urinary tract colonization due to specific binding to α-D-galactopyranosyl-(1-4)-β-D-galactopyranoside receptors in the kidneys. Thus, inhibiting P-fimbrial adhesion may reduce the incidence of UPEC-mediated UTI. E. coli 83972 is an asymptomatic bacteriuria isolate successfully used as a prophylactic agent to prevent UTI in human studies. We constructed a recombinant E. coli 83972 strain displaying a surface-located oligosaccharide P fimbriae receptor mimic that bound to P-fimbriated E. coli producing any of the 3 PapG adhesin variants. The recombinant strain, E. coli 83972:: lgtCE, impaired P fimbriae-mediated adhesion to human erythrocytes and kidney epithelial cells. Additionally, E. coli 83972::lgtCE impaired urine colonization by UPEC in a mouse UTI model, demonstrating its potential as a prophylactic agent to prevent UTI.
Urinary tract infections (UTIs) caused by uropathogenic Escherichia coli (UPEC) are a significant health concern, exacerbated by the rapid emergence of multidrug resistant strains refractory to antibiotic treatment. P fimbriae are strongly associated with upper urinary tract colonization due to specific binding to α-D-galactopyranosyl-(1-4)-β-D-galactopyranoside receptors in the kidneys. Thus, inhibiting P-fimbrial adhesion may reduce the incidence of UPEC-mediated UTI. E. coli 83972 is an asymptomatic bacteriuria isolate successfully used as a prophylactic agent to prevent UTI in human studies. We constructed a recombinant E. coli 83972 strain displaying a surface-located oligosaccharide P fimbriae receptor mimic that bound to P-fimbriated E. coli producing any of the 3 PapG adhesin variants. The recombinant strain, E. coli 83972:: lgtCE, impaired P fimbriae-mediated adhesion to human erythrocytes and kidney epithelial cells. Additionally, E. coli 83972::lgtCE impaired urine colonization by UPEC in a mouse UTI model, demonstrating its potential as a prophylactic agent to prevent UTI.
Urinary tract infections (UTIs) are among the most common infectious diseases of humans, with an estimated 150 million cases per year [1] . The recurrence rate is high, and infections frequently become chronic after multiple episodes. Bacterial interference using nonvirulent bacteria to prevent infection by pathogens is an alternative therapy for patients with chronic and recurrent UTIs that do not respond to antimicrobial treatment [2] . Escherichia coli 83972 is a clinical asymptomatic bacteriuria (ABU) isolate capable of long-term bladder colonization without causing disease symptoms and has been effectively used as a prophylactic agent for the prevention of UTI in studies involving humans [2] [3] [4] [5] . E. coli 83972 does not adhere to host cells or induce a host inflammatory response because notable virulence determinants, including P, type 1, and F1C fimbriae are attenuated in this strain [6] [7] [8] . In clinical studies, patients deliberately colonized with E. coli 83972 by bladder inoculation did not develop systemic illness, had reduced frequency of symptomatic UTI, and reported a subjective increase in quality of life [2] [3] [4] [5] .
Uropathogenic E. coli (UPEC) is the most common etiological agent of UTI. UPEC cause >80% of UTIs, and in many cases these strains are resistant to multiple different antibiotics [9, 10] . The ability of UPEC to colonize the urinary tract and cause disease is strongly associated with the expression of fimbrial adhesins [11] . Adherence to the uroepithelium enables UPEC to resist the hydrodynamic forces of urine flow, trigger host and bacterial cell-signaling pathways, and establish infection. Among the characterized UPEC adhesins, P and type 1 fimbriae correlate with uropathogenesis and mediate binding to specific receptors within the urinary tract [12] [13] [14] [15] . UPEC P fimbriae are most strongly associated with colonization of the upper urinary tract [14] , and UPEC strains that cause pyelonephritis commonly encode multiple copies of P fimbriae gene clusters in their genome [16] . P fimbriae contribute to colonization by binding to the α-D-galactopyranosyl-(1-4)-β-D-galactopyranoside receptor epitope in the globoseries of glycolipids found in human kidneys and on erythrocytes [17, 18] . P fimbriae recognize their receptors by virtue of the organelle tip-located adhesin PapG; 3 major classes of PapG adhesins have been characterized (PapGI, PapGII, and PapGIII), and these preferentially bind to different Galα [1 → 4] Galβ epitopes [17, 18] . P fimbriae contribute to uroepithelial cell adherence and induction of innate immune responses in animals and humans [8, 14, 19] . Therefore, inhibiting P-fimbrial adhesion may not only prevent urinary tract colonization by UPEC, but may also prevent the induction of inflammation in the kidney that can result in the acute pathology seen in cases of pyelonephritis.
Several studies have demonstrated that oligosaccharide receptor mimics inhibit the attachment of bacterial adhesins and toxins to host cells [20, 21] . Paton and colleagues developed a method to engineer recombinant bacteria expressing oligosaccharide receptor mimics on their cell surface, using heterologous galactosyltransferase genes [22] . This technology was used to create several probiotics, including a Shiga toxin (Stx) receptor mimic, a heat-labile enterotoxin receptor mimic, and a cholera toxin receptor mimic [20, 22] . We have used this technology to construct a recombinant E. coli 83972 strain displaying a P fimbriae receptor mimic on its surface. The galactosyltransferase genes lgtC and lgtE from Neisseria meningitidis and Neisseria gonorrhoeae, respectively, encoding synthesis of the oligosaccharide Galα[1 → 4]Galβ[1 → 4]Glc-(the known receptor for Stx), were inserted into the chromosome of E. coli 83972. We hypothesized that expression of the lgtCE genes would modify the naturally rough lipopolysaccharide (LPS) outer core of E. coli 83972 into a P fimbriae receptor mimic. Here, we assessed the ability of the recombinant strain E. coli 83972::lgtCE to bind to P-fimbriated E. coli, inhibit P fimbriae-mediated adhesion to human cells, and prevent colonization of the mouse urinary tract by P-fimbriated UPEC.
METHODS

Bacterial Strains, Plasmids, and Growth Conditions
Strains and plasmids used in this study are described in Table 1 . P-fimbriated strains MS1250, MS1251, and MS1253 were constructed by transforming previously described plasmids encoding P-fimbrial genes into E. coli DH5α. Strain MS1250 contains plasmid pRHU845, which encodes the pap gene cluster from UPEC strain J96 ( papGI allele) [27] . Strain MS1251 contains plasmid pPIL110-35, which encodes the pap gene cluster from UPEC strain AD110 ( papGII allele) [28] . Strain MS1253 contains plasmid pJFK102, which encodes the prs gene cluster from UPEC J96 ( papGIII allele) [29] . Strains were routinely grown at 37°C on solid or in liquid LuriaBertani (LB) medium. LB agar plates were supplemented with appropriate antibiotics in the following final concentrations: 50 µg mL -1 ampicillin, 50 µg mL -1 kanamycin, 15 µg mL -1 tetracycline, and 15 µg mL -1 chloramphenicol.
Construction of the Recombinant Strain E. coli 83972::lgtCE
To construct E. coli 83972::lgtCE, the lgtCE genes from pJCPGb 3 [22] were integrated into the chromosome of E. coli 83972. First, the lgtCE genes from plasmid pJCP-Gb 3 were amplified by polymerase chain reaction (PCR) using primers 1931 (5′-TGACCATGATTACGAATTCG) and 1932 (5′-GC GCCGTCGACTAAGTTGGGTAACGCCAGGG). The PCR product was digested with SalI and ligated into EcoRV/SalIdigested pBR322 downstream of the constitutive tetracycline resistance gene promoter to create plasmid pRW13. Next, the kanamycin resistance gene (kan) and FLP recognition target (FRT) sites were amplified from pKD4, using primers 2060 (5′-GCGGCGTCGACGTGTAGGCTGGAGCTGCTTC) and 2061 (5′-CCCGCGTCGACCATATGAATATCCTCCTTAG). The PCR product was digested with SalI and ligated into SalIdigested pRW13 downstream of the lgtCE genes to create pRW16. The λ Red recombination method was used as previously described [31] to insert the lgtCE-kan genes from pRW16 into E. coli 83972 within the nonfunctional type 1 fimbrial gene cluster (ie, between fimD and fimH). The lgtCEkan genes were PCR amplified from pRW16, using primers 2063 (5′-ATGGCAGCATATCAATACCTGGCTTGAGCGA GACATAATTCCGTTACGTTACATATTTGAATGTATTTAG) and 2064 (5′-TACTGCTCCTAACGATACCGTGTTATTCGC TGGAATAATCGTACCGTTGCTCTCAAGGGCATCGGTCG AC), which contain 50-base-pair ends (5′) complementary to the fim gene cluster allowing homologous recombination. The PCR product was transformed into E. coli 83972( pKD46) to construct the recombinant strain E. coli 83972fim'::lgtCE (referred to as 83972::lgtCE). E. coli 83972::lgtCE was confirmed by PCR and DNA sequencing with primers 97 (5′-CAA TATTCGTCATACTGTCTGG), 1924 (5′-CGCAATCGGCAA TGTATTCG), 78 (5′-CGGCCACAGTCGATGAATCC), and 331 (5′-GCAGTCACCTGCCCTCCGGTA).
Stx Adsorption/Neutralization Assay
Stx neutralization was assayed as previously described, using 10 µg mL -1 purified Stx2 or a lysate of E. coli JM109:pJCP525
as a source of Stx1 [22] .
Agglutination Assays
E. coli strains 83972, 83972( pJCP-Gb 3 ) and 83972::lgtCE were grown in LB medium shaking at 37°C for 16 hours. Strain 83972( pJCP-Gb 3 ) was induced for lgtCE expression, using 1 mM IPTG. P-fimbriated E. coli strains MS1250, MS1251, and MS1253 and UPEC strain CFT073 were grown on LB agar plates at 37°C for 16 hours and subsequently resuspended in phosphate-buffered saline. Cell suspensions were standardized to an optical density at 600 nm of 1.0; a volume of 10 µL of an E. coli 83972 strain was mixed with 10 µL of a P-fimbriated strain on glass slides, and the presence or absence of visible agglutination was recorded. Agglutination between fluorescently labeled strains OS56( pPIL110-35), 83972( pmCherry), and 83972::lgtCE( pmCherry) was performed as described above and observed using an LSM 510 META confocal microscope (Zeiss). Hemagglutination using human type A red blood cells (RBCs) was assessed as previously described [32] . Strains were grown as for mixed agglutinations, except tryptic soy agar plates were used to optimize P-fimbrial expression [33] . E. coli 83972 or 83972::lgtCE were mixed with P-fimbriated strains MS1251 and CFT073 in 1:1, 5:1, or 10:1 ratios before 20 µL of the combined strains were mixed with 10 µL of RBCs. Hemagglutination was assessed visibly for up to 5 minutes, with the time taken to cause agglutination recorded.
Kidney Epithelial Cell Adhesion Assays
Human A498 kidney epithelial cells were grown in Advanced MEM supplemented with 10% heat-inactivated fetal bovine serum (Gibco 
, and kanamycin (83972::lgtCE). Animal experimentation was approved by the animal ethics committee of Griffith University (number MSC/14/08AEC).
Statistical Analysis
Differences in hemagglutination times and bacterial adherence to kidney epithelial cells (in CFU per mL) were tested using unpaired 2-sample t tests with Minitab 14 statistical software. Differences in mouse UTI colonization by E. coli CFT073 CAM (CFU/mL or CFU/0.1 g) were tested using the nonparametric Mann-Whitney U test. The level of statistical significance was set at P < .05.
RESULTS
Construction of the
Plasmid pJCP-Gb 3 contains the galactosyltransferase lgtCE genes that direct synthesis of the oligosaccharide Galα [1 → 4] Galβ [1 → 4] Glc-at the distal end of the E. coli LPS core, both in strains such as CWG308, which has a waaO mutation that truncates the LPS core so that it terminates in Glc [22] , as well as in other strains of E. coli and Salmonella enterica with wildtype LPS core regions, wherein the overexpressed heterologous transferases outcompete the endogenous enzymes for the Glcterminating LPS core intermediate [35] .
) suspensions were tested for their capacity to bind and neutralize Stx1 and Stx2. In both cases, >99% of toxin was neutralized. LPS extracts were also analyzed by polyacrylamide gel electrophoresis and silver staining. Both toxin neutralization capacity and LPS profile were indistinguishable from that previously reported [22] for E. coli CWG308:pJCP-Gb 3 (data not shown). However, to ensure stable expression of the Galα[1 → 4]Galβ[1 → 4]Glctrisaccharide, a strategy was devised to integrate the lgtCE genes from pJCP-Gb 3 into the chromosome of E. coli 83972 (Figure 1 ). This resulted in the construction of the recombinant strain E. coli 83972fim'::lgtCE (referred to as 83972::lgtCE). We hypothesized that expression of the Galα[1 → 4]Galβ[1 → 4]Glc-trisaccharide should result in binding of E. coli 83972::lgtCE to P-fimbriated E. coli.
E. coli 83972::lgtCE Agglutinates P-fimbriated E. coli
We examined whether E. coli 83972::lgtCE expressing Galα[1 → 4]Galβ[1 → 4]Glc-on the cell surface could agglutinate P-fimbriated E. coli. E. coli strains 83972 or 83972::lgtCE were mixed 1:1 with P-fimbriated strains MS1250 ( papGI allele), MS1251 ( papGII allele), MS1253 ( papGIII allele), or UPEC CFT073 (which contains 2 chromosomally encoded pap gene clusters-both papGII alleles) and monitored for visible agglutination. E. coli 83972::lgtCE agglutinated all PapG variant P-fimbriated E. coli strains. As expected, E. coli 83972 did not bind to any of the P-fimbriated strains. To visualize the specific agglutination of E. coli 83972::lgtCE with a Pfimbriated strain, we used fluorescently labeled strains in combination with confocal scanning laser microscopy. First, plasmid pPIL110-35 ( papGII) was transformed into E. coli OS56 to generate a P-fimbriated, green fluorescent strain OS56( pPIL110-35). Plasmid pmCherry was transformed into both E. coli 83972 and 83972::lgtCE to obtain fluorescently tagged strains. Strains were mixed 1:1 and examined for agglutination. As expected, no agglutination was observed for E. E. coli 83972::lgtCE Impairs Binding of P-fimbriated E. coli to Human RBCs P fimbriae adhere to and agglutinate human RBCs via specific interaction with Galα[1 → 4]Galβ saccharides [17] . Hemagglutination assays were performed to assess whether E. coli 83972::lgtCE could inhibit the ability of P-fimbriated E. coli to agglutinate RBCs. We tested the ability of MS1251 ( papGII) and UPEC CFT073 to bind to RBCs in the presence of E. coli 83972 or 83972::lgtCE. Wild-type E. coli 83972 had no effect on MS1251 or CFT073 hemagglutination times when mixed 1:1, 5:1, or 10:1 with the P-fimbriated strains (Figure 3) . However, E. coli 83972::lgtCE significantly increased the MS1251 hemagglutination times when mixed 5:1 or 10:1, compared with E. coli 83972 (P < .05). A more pronounced effect was seen for E. coli CFT073, in which a 1:1 ratio of 83972::lgtCE and CFT073 was enough to significantly increase the hemagglutination time, compared with E. coli 83972 (P < .05). Additionally, at a 10:1 ratio of 83972::lgtCE to CFT073, there was no visible hemagglutination after 5 minutes. Thus, E. coli 83972::lgtCE interferes with the binding of P-fimbriated bacteria to human cells.
E. coli 83972::lgtCE Impairs Binding of P-fimbriated E. coli to Human Kidney Cells P fimbriae adhere to human kidney epithelial cells, and this is strongly associated with colonization of the upper urinary tract [19] . To further demonstrate that E. coli 83972::lgtCE interferes with the function of P fimbriae as an adhesin, quantitative adhesion assays using A498 human kidney cells were performed. We tested the ability of P-fimbriated strains MS1251 ( papGII) and CFT073
CAM to adhere to kidney cells in the presence of E. coli 83972 AMP or 83972::lgtCE. Strain MS1251 adherence to kidney cells was 92% lower when mixed with 83972::lgtCE than when mixed with strain 83972 AMP (P < .05; Figure 4 ). Additionally, strain CFT073 CAM adherence to kidney cells was 72% lower in the presence of 83972::lgtCE, compared with 83972 AMP (P < .05). Therefore, E. coli 83972::
lgtCE impaired the kidney epithelial cell adhesion of P-fimbriated E. coli, including UPEC strain CFT073 CAM . 
E. coli 83972::lgtCE Impairs UPEC Colonization in a Mouse UTI Model
A mouse UTI model was used to determine whether E. coli 83972::lgtCE could inhibit urinary tract colonization by Pfimbriated UPEC. E. coli 83972 AMP or 83972::lgtCE were mixed 100:1 with UPEC strain CFT073 CAM and inoculated into the bladder of C57BL/6 mice. The median number of E. coli CFT073 CAM recovered from the urine was significantly lower in mice that were challenged with a mixed inoculum containing E. coli 83972::lgtCE, compared with those that received a mixed inoculum containing 83972 AMP (P = .014; Figure 5 ). There was no difference in the median number of E. coli CFT073 CAM recovered from the bladder or kidneys when mixed with E. coli 83972::lgtCE or when mixed with 83972 AMP (P = .175 and P = .456, respectively; data not shown). Thus, E. coli 83972::lgtCE expressing a P fimbriae oligosaccharide receptor mimic significantly prevented urine colonization by UPEC in the mouse UTI model.
DISCUSSION
In this study, we successfully engineered an E. coli 83972 strain that stably expresses a P fimbriae receptor mimic on the bacterial surface. We then assessed the ability of E. coli 83972:: lgtCE to bind to P-fimbriated bacteria and to inhibit adhesion of P-fimbriated bacteria to host cells. E. [17, 18] . The binding of E. coli 83972::lgtCE to PapGII is clinically relevant because papGII is the most highly prevalent allele among clinical UPEC isolates and is associated with human pyelonephritis and bacteremia [36, 37] . The finding that E. coli 83972::lgtCE bound to all 3 classes of PapG adhesins suggests it may be effective against all Pfimbriated UPEC. E. coli 83972::lgtCE also impaired adhesion of P-fimbriated bacteria to both human erythrocytes and human kidney epithelial cells. Adherence of both MS1251 ( papGII) and CFT073 to human cells was impaired by E. coli 83972::lgtCE, with differences in effectiveness most likely due to the different levels of P-fimbrial expression between these strains. Previous studies with UPEC strain CFT073 have demonstrated that even under optimal conditions for P fimbriae expression, <20% of the bacterial population will be P fimbriated [38, 39] . Thus, we demonstrated that E. coli 83972::lgtCE prevents adhesion of P-fimbriated E. coli, including the wild-type UPEC strain CFT073, to host cells by competitive inhibition. We also tested whether E. coli 83972::lgtCE could prevent urinary tract colonization by P-fimbriated E. coli, using a mouse UTI model. In a mixed infection assay, the number of E. coli CFT073 cells recovered from the urine of infected mice was significantly lower in mice inoculated with E. coli 83972::lgtCE as compared to 83972 AMP . E. coli 83972 asymptomatically colonizes the urine of humans but cannot ascend to the kidneys [40] . The finding that E. coli 83972::lgtCE impairs colonization of the urine by a P-fimbriated strain suggests it may be effective at preventing high-grade bacteriuria and subsequent kidney ascension by UPEC in humans.
Oligosaccharide receptor mimics are unlikely to exhibit toxicity, are poorly immunogenic, and would not be expected to promote resistance [21, 41] . Several previous studies have examined the ability of both natural and synthetic receptor mimics to inhibit P fimbriae-mediated adhesion [42] [43] [44] [45] [46] [47] . Human milk oligosaccharides act as anti-adhesives against Pfimbriated UPEC, and digalactoside-containing glycoproteins from pigeon and dove eggs reduced kidney infection by Pfimbriated E. coli in a mouse UTI model [42, 44] . Globotriose, mimicking Gb 3 , inhibited and reversed binding of a Pfimbriated E. coli strain to human RBCs and decreased colonization of the mouse urinary tract [43] . Globotetraose, mimicking Gb 4 , also decreased adhesion of a P-fimbriated E. coli strain to exfoliated human uroepithelial cells and decreased colonization of the mouse urinary tract [47] . However, synthetic oligosaccharide receptor mimics have not yet been used successfully in patients to prevent or treat infections.
Recombinant bacteria expressing oligosaccharide receptor mimics have several advantages over free, soluble oligosaccharides, which often need to be in a specific multivalent conformation, can be expensive and may be rapidly digested if administered orally [20, 21] . Indeed, the Stx receptor mimic has a binding capacity 10 000 times that of the synthetic Stx absorbent Synsorb Pk, which was used safely in humans but failed to prevent disease in phase II clinical trials [22, 41, 48] . E. coli 83972 is well maintained in the bladder, does not adhere to the uroepithelium or induce immune responses, outcompetes UPEC, and has been successfully used in patients to reduce symptomatic UTI [40] . Phase I and II clinical trials with E. coli 83972 have been performed in Sweden and the United States, with additional trials planned [2] [3] [4] [5] . The epitope Galα [1 → 4] Galβ [1 → 4] Glc-occurs naturally on human cells, including uroepithelial cells, and was found to be safe for administration to children as part of Synsorb Pk [48] . Therefore, E. coli 83972:: lgtCE expressing the same epitope is likely to be safe in patients. Using plasmid pCP20, we have now removed the kanamycin resistance cassette from E. coli 83972::lgtCE, resulting in the creation of an E. coli 83972::lgtCE strain with no antibiotic resistance marker that may be a more viable option for use as a probiotic. We predict that E. coli 83972::lgtCE, like wild-type E. coli 83972, would be most beneficial for patients highly susceptible to UTI, such as those individuals with a neurogenic bladder or catheterized patients. Overall, the recombinant E. coli receptor mimic strain described here may represent an alternative prophylactic treatment for patients with chronic or recurrent UTIs, a desperately needed alternative given the rapid emergence of multidrugresistant UTI strains refractive to current treatment regimens.
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